Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.The Lancet. Haematology · 2022Trial
- Decoding cytarabine-induced damage in the prepubertal testis: A multi-omics atlas of ecosystem and inheritance.iScience · 2026Article
- Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.Bone marrow transplantation · 2025Article
- Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach.Internal medicine journal · 2025Article
- Risk Stratification in Older Intensively Treated Patients With AML.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.Frontiers in oncology · 2024Review
- A Question of Frame: The Role of the Bone Marrow Stromal Niche in Myeloid Malignancies.HemaSphere · 2023Review
- Review
- Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Blood advances · 2023Article
- Oncology stewardship in acute myeloid leukemia.Annals of hematology · 2022Review
- Article
- Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.Pediatric blood & cancer · 2022Article
- Article
- Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?Current oncology reports · 2021Review
- Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 3 countries.
Funding
Abstract
purposeThe optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is uncertain. The United Kingdom National Cancer Research Institute AML17 trial randomly assigned patients who were not high risk to a total of three versus four courses. PATIENTS AND
methodsPatients received two induction courses based on daunorubicin and cytarabine (Ara-C), usually with gemtuzumab ozogamicin. Following remission, 1,017 patients were randomly assigned to a third course, MACE (amsacrine, Ara-C, and etoposide), plus a fourth course of MidAc (mitoxantrone and Ara-C) and following an amendment to one or two courses of high-dose Ara-C. Primary end points were cumulative incidence of relapse (CIR), relapse-free survival (RFS), and overall survival (OS). Outcomes were correlated with patient characteristics, mutations, cytogenetics, induction treatments, and measurable residual disease (MRD) postinduction.
resultsIn logrank analyses, CIR and RFS at 5 years were improved in recipients of four courses (50%
conclusionAlthough a fourth course of high-dose Ara-C reduced CIR and improved RFS, it did not result in a significant OS benefit. Subsets including those with favorable cytogenetics, those lacking a mutation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.